Japanese multinational Takeda Pharmaceutical has set its scope on the global market after the company's CEO publicised its new strategy in an interview with CNBC on Tuesday.

Takeda president and CEO Christophe Weber said that globalisation was central to the firm's ongoing strategy. He explained that rather than limiting product releases to a handful of countries at a time, the company wants to launch them globally.

In addition to the more ambitious product launches, the company has also placed an emphasis on innovation; with Weber commenting that Takeda will only develop treatments with "high innovation potential".

Weber also detailed the three main therapy areas the company will focus on: gastroenterology, oncology and the central nervous system.

Weber is the company's first non-Japanese CEO and is under significant pressure to improve profits. Speaking to CNBC, he said: "I think when you transform a company, you need to understand where your starting point [is and] where you want to go, and also define the pace of change. Not too fast, not too slow.

"We have done a lot on many fronts: on the commercial front, on the R&D, on the manufacturing. I will say that we have done the heavy lifting of the transformation and we are starting now to see the result, which is nice."